Section Arrow
OPT.NASDAQ
- Opthea Limited
  suspend
Quotes are at least 15-min delayed:2025/11/15 09:17 EST
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
3.41 
1-M High
-- 
Volume 
-- 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
524.82M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.38 
20-SMA 4.1 
50-SMA 4.43 
52-W High 6.3 
52-W Low 3.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.06/-0.11
Enterprise Value
666.38M
Balance Sheet
Book Value Per Share
-1.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
25.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/15 09:17 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.